Baker BROS. Advisors LP Acquires Shares of 875,796 Abivax SA Sponsored ADR $ABVX

Baker BROS. Advisors LP bought a new position in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) during the 3rd quarter, HoldingsChannel.com reports. The fund bought 875,796 shares of the company’s stock, valued at approximately $74,355,000. Abivax makes up approximately 0.5% of Baker BROS. Advisors LP’s holdings, making the stock its 24th biggest position.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. EverSource Wealth Advisors LLC grew its holdings in shares of Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after acquiring an additional 369 shares in the last quarter. First Horizon Corp purchased a new position in Abivax in the third quarter worth $36,000. Bank of America Corp DE grew its stake in Abivax by 56.1% in the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after purchasing an additional 1,990 shares during the period. Hantz Financial Services Inc. bought a new position in Abivax in the 3rd quarter valued at $52,000. Finally, Cubist Systematic Strategies LLC increased its position in shares of Abivax by 34.3% during the 1st quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock valued at $63,000 after purchasing an additional 2,595 shares during the last quarter. Hedge funds and other institutional investors own 47.91% of the company’s stock.

Abivax Stock Performance

NASDAQ ABVX opened at $115.50 on Friday. The company’s 50 day moving average is $118.99 and its 200-day moving average is $108.89. Abivax SA Sponsored ADR has a 12-month low of $4.77 and a 12-month high of $148.83. The company has a quick ratio of 7.86, a current ratio of 7.86 and a debt-to-equity ratio of 0.03. The firm has a market cap of $9.13 billion, a P/E ratio of -27.63 and a beta of 1.00.

Abivax (NASDAQ:ABVX) last released its quarterly earnings data on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The company had revenue of ($4.92) million for the quarter. Sell-side analysts predict that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current year.

Wall Street Analyst Weigh In

ABVX has been the topic of a number of recent analyst reports. Citizens Jmp lifted their target price on Abivax from $114.00 to $131.00 and gave the stock a “market outperform” rating in a research note on Tuesday, December 16th. BTIG Research restated a “buy” rating and set a $150.00 price objective on shares of Abivax in a report on Wednesday, February 25th. Wall Street Zen lowered shares of Abivax from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Morgan Stanley boosted their target price on shares of Abivax from $101.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, January 9th. Finally, Oppenheimer set a $131.00 price target on shares of Abivax in a research note on Thursday, January 8th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Abivax presently has a consensus rating of “Moderate Buy” and a consensus target price of $134.75.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.